Clinical Trials Directory

Trials / Completed

CompletedNCT02187224

Progesterone Effect on Individuals Diagnoses With AD and PTSD.

Progesterone Treatment in Reducing Trauma and Alcohol Induced Craving in Individuals Diagnoses With Alcohol Dependence (AD) and Post-tramatic Stress Disorder (PTSD).

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
13 (actual)
Sponsor
Yale University · Academic / Other
Sex
All
Age
21 Years – 60 Years
Healthy volunteers
Not accepted

Summary

This is a randomized control trial with an anticipated 36 participants diagnosed with post-traumatic stress disorder (PTSD) and comorbid alcohol dependence. Participants will be randomized to receive either progesterone (200 mg. bid) or placebo in identical looking capsules for three days. One goal of this research study is to test if progesterone is more effective than placebo in reducing craving after exposure to trauma cues and alcohol cues in a laboratory paradigm among men and women with AD and PTSD. We hypothesize that progesterone in comparison to placebo will significantly reduce craving for alcohol in response to trauma cues alone and in combination with alcohol cues in individuals with AD and PTSD. A second goal is to examine if there are gender differences in progesterone effects on stress and alcohol cue-induced craving. We hypothesize that the effects of progesterone on stress and craving will be stronger in women than in men. Participants will be recruited primarily through advertisement, but also through the clinical facilities at the VA and from other collaborators.

Conditions

Interventions

TypeNameDescription
DRUGProgesterone
DRUGPlacebo (for Progesterone)

Timeline

Start date
2016-09-01
Primary completion
2021-09-08
Completion
2021-09-08
First posted
2014-07-10
Last updated
2023-04-26
Results posted
2023-04-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02187224. Inclusion in this directory is not an endorsement.

Progesterone Effect on Individuals Diagnoses With AD and PTSD. (NCT02187224) · Clinical Trials Directory